New pain shot could replace catheters after leg amputation

NCT ID NCT05140499

Terminated Symptom relief Sponsor: Aurora Quaye Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two standard pain relief methods after below-knee amputation: a long-lasting numbing injection (liposomal bupivacaine) versus a continuous nerve catheter that delivers numbing medicine. The goal was to see which provides better pain control and reduces the need for opioids. Only 11 people took part before the study was stopped early, so the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liposomal bupivacaine (Exparel) and bupivacaine hydrochloride
What this could lead to: If this works, it could show that a single injection controls pain as well as a catheter, possibly reducing opioid use and simplifying recovery after amputation.
What could go wrong: This is a very small pilot study (11 participants) that was terminated early, so results are preliminary and may not apply widely. Neither method is new, so the upside is modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMPUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMPUTATION PAIN, POSTOPERATIVE

Contacts and locations

Locations

Maine Medical Center

Portland, Maine, 04102, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.